U.S. License Holder:
Janssen Biotech
Date of License:
May-21-2021
Last Update:
Apr-30-2024
FDA-Approved Indications
RYBREVANT (amivantamab-vmjw) is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated:
In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test;
As a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.